The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Economic burden of tyrosine kinase inhibitor (TKI) treatment failure in patients with chronic myeloid leukemia (CML).
Yaozhu J Chen
Employment or Leadership Position - IMS Health
Hui Huang
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Victoria Divino
Employment or Leadership Position - IMS Health
Shibani Pokras
Employment or Leadership Position - IMS Health
Shawn Hallinan
No relevant relationships to disclose
Julie Munakata
Employment or Leadership Position - IMS Health
Catherine Taylor
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Lisa McGarry
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Daniel Ng
Stock Ownership - ARIAD
Christopher Nieset
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Kevin B. Knopf
Consultant or Advisory Role - ARIAD